REGN1193
R1193-DM-1402
Phase 1 small_molecule terminated
Quick answer
REGN1193 for Diabetes Mellitus, Type 2 is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated